pharma news

Oct 20, 2020

Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia   The US FDA has granted its full approval to Venclexta (venetoclax) for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older who are unfit for intensive induction chemotherapies.  The approval is based on the res...

Oct 15, 2020

Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback caused Cyclerion to switch its focus to IW-6463 and to treat central nervous system diseases....

Oct 08, 2020

Designing a universal flu vaccine by focusing on the immune system  A universal flu vaccine that can foster protection to people against any influenza strain is considered a goal in flu research as it could spare scientists from the often erroneous process of predicting the circulating strains each year and...

Oct 06, 2020

MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion  Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree.  BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...

Sep 29, 2020

Inovio’s shares plunge after FDA holds-off its COVID-19 vaccine Phase II/III trial  Inovio’s COVID-19 vaccine, INO-4800, Phase II/III clinical trials’ have been put under partial hold after the USFDA raised questions. The firm mentioned the reason behind the halt of the trials is not due to adverse events i...

Sep 22, 2020

Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca  Samsung Biologics announced the conclusion of a long-term supply deal with AstraZeneca worth USD 330.8 Million.  AZ has made several headlines the past few months, forming a slew of deals to manufacture and supply its products. H...

Sep 10, 2020

Pfizer, BioNTech report shows the immune response in animals to COVID-19  Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, each based on a different mRNA format. The companies are now exhibiting that the most advanced candidate, BNT162b2, performed well in trials in ...

Sep 08, 2020

Cycle Pharmaceuticals Hauls In USD 25 Million In A Debt Financing Agreement  Cycle Pharmaceuticals, a biotech company focusing exclusively on rare diseases, announced a strategic financing agreement worth USD25 million credit facility with Deutsche Bank AG.  Headquartered in the UK, Cycle Pharmaceut...

Sep 01, 2020

Nestle acquires peanut allergy treatment with USD 2 Billion Aimmune buyout Nestle has announced a definitive agreement to extend its acquisition of Aimmune Therapeutics. Nestle will pay an additional amount of USD 2 Billion to buy the remaining shares of Aimmune. With the acquisition, Nestle will gain Aimmune's ...

Aug 27, 2020

Moderna's COVID-19 vaccine triggers an immune response in older adults Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. The phase 1 study that is being run by the National ...